Ultrasensitive techniques and protein misfolding amplification assays for biomarker-guided reconceptualization of Alzheimer's and other neurodegenerative diseases.
Nicole CampeseMaria Francesca BeatinoClaudia Del GambaElisabetta BelliLinda GiampietriEleonora Del PreteAlessandro GalganiAndrea VergalloGabriele SicilianoRoberto CeravoloHarald HampelFilippo BaldacciPublished in: Expert review of neurotherapeutics (2021)
Ultrasensitive assays represent innovative solutions for blood-based assessments during the entire Alzheimer's disease (AD) biological and clinical continuum, for contexts of use (COU) such as prediction, detection, early diagnosis, and prognosis of AD. Moreover, cerebrospinal fluid (CSF)-based misfolding amplification assays show encouraging performance in detecting α-synucleinopathies in prodromal or at-high-risk individuals and may serve as tools for patients' stratification by the presence of α-synuclein pathology. Further clinical research will help overcome current methodological limitations, also through exploring multiple accessible bodily matrices. Eventually, integrative longitudinal studies will support precise definitions for appropriate COU across NDDs.
Keyphrases
- label free
- cerebrospinal fluid
- high throughput
- end stage renal disease
- gold nanoparticles
- cognitive decline
- ejection fraction
- chronic kidney disease
- newly diagnosed
- quantum dots
- nucleic acid
- peritoneal dialysis
- prognostic factors
- molecularly imprinted
- patient reported outcomes
- parkinson disease
- small molecule
- mass spectrometry